Antlia Bioscience, Inc.

Antlia Bioscience, Inc. is a biotechnology startup founded in 2020 with a mission to develop revolutionary therapeutics for chronic diseases. Utilizing its proprietary chemistry platform, PASylation®, the company is focused on engineering long-acting peptides with refined pharmacologic and pharmacokinetic properties. This approach allows for the creation of promising treatments for a range of chronic illnesses. The company's dedication to making a profound impact in the treatment of cardiovascular and pulmonary diseases is reflected in its slogan, "Turning promising peptides into groundbreaking therapeutics for chronic diseases." Antlia Bioscience's commitment is underpinned by a team of devoted scientists and advisors, as well as collaborative partnerships with esteemed professionals who share the vision of bringing life-changing therapies to the market. As of now, there is no publicly available information regarding the company's latest investment or the involved investors. With its stronghold in the United States, Antlia Bioscience is poised to become a notable player in the biotechnology and healthcare industries.